Drug Profile
TD 101
Alternative Names: Pachyonychia congenita siRNA; Reveker; sdTD-K6a.513a.12; siRNA sdTD101; TD-K6a.513a.12; TD101Latest Information Update: 20 Apr 2016
Price :
$50
*
At a glance
- Originator TransDerm
- Developer International Pachyonychia Congenita Consortium; PC Project; TransDerm
- Class Skin disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pachyonychia congenita
Most Recent Events
- 20 Apr 2016 No recent reports on development identified - Preclinical for Pachyonychia congenita in USA (Topical)
- 17 Jan 2008 Phase-I clinical trials in Pachyonychia congenita in USA (Intradermal)